Artizan's Biobanking

Artizan’s world-class biobanking program enables our research team to examine microbial drivers in many different disease types, leading to the creation of novel small molecule compounds that inhibit specific microbial virulence factors and arrest pathogenesis.

The company’s flagship biobanking program, IBD-BIOME, collected clinical data from over 1,500 proprietary longitudinal samples from nearly 300 inflammatory bowel disease (IBD) patients and 200 healthy controls and initial interrogation using our drug discovery platform and IgA-SEQ™ technology allowed us to identify three clinical drug candidates intended for treatment of IBD.